Orally Active Epoxyeicosatrienoic Acid Analogs

William B. Campbell, John D. Imig, James M. Schmitz, J R Falck

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Biologically active epoxyeicosatrienoic acid (EET) regioisomers are synthesized from arachidonic acid by cytochrome P450 epoxygenases of endothelial, myocardial, and renal tubular cells. EETs relax vascular smooth muscle and decrease inflammatory cell adhesion and cytokine release. Renal EETs promote sodium excretion and vasodilation to decrease hypertension. Cardiac EETs reduce infarct size after ischemia-reperfusion injury and decrease fibrosis and inflammation in heart failure. In diabetes, EETs improve insulin sensitivity, increase glucose tolerance, and reduce the renal injury. These actions of EETs emphasize their therapeutic potential. To minimize metabolic inactivation, 14,15-EET agonist analogs with stable epoxide bioisosteres and carboxyl surrogates were developed. In preclinical rat models, a subset of agonist analogs, termed EET-A, EET-B, and EET-C22, are orally active with good pharmacokinetic properties. These orally active EET agonists lower blood pressure and reduce cardiac and renal injury in spontaneous and angiotensin hypertension. Other beneficial cardiovascular actions include improved endothelial function and cardiac antiremodeling actions. In rats, EET analogs effectively combat acute and chronic kidney disease including drug- and radiation-induced kidney damage, hypertension and cardiorenal syndrome kidney damage, and metabolic syndrome and diabetes nephropathy. The compelling preclinical efficacy supports the prospect of advancing EET analogs to human clinical trials for kidney and cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)211-224
Number of pages14
JournalJournal of Cardiovascular Pharmacology
Issue number4
StatePublished - Oct 1 2017


  • diabetes
  • epoxyeicosatrienoic acid
  • epoxygenase
  • heart failure
  • hypertension
  • inflammation
  • kidney injury

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Orally Active Epoxyeicosatrienoic Acid Analogs'. Together they form a unique fingerprint.

Cite this